{"id":"https://openalex.org/W2018654936","doi":"https://doi.org/10.1517/13543770903313753","title":"PDE4 inhibitors: a review of current developments (2005 \u2013 2009)","display_name":"PDE4 inhibitors: a review of current developments (2005 \u2013 2009)","publication_year":2009,"publication_date":"2009-10-16","ids":{"openalex":"https://openalex.org/W2018654936","doi":"https://doi.org/10.1517/13543770903313753","mag":"2018654936","pmid":"https://pubmed.ncbi.nlm.nih.gov/19832118"},"language":"en","primary_location":{"id":"doi:10.1517/13543770903313753","doi":"https://doi.org/10.1517/13543770903313753","is_oa":false,"landing_page_url":"https://doi.org/10.1517/13543770903313753","pdf_url":null,"source":{"id":"https://openalex.org/S3784663","display_name":"Expert Opinion on Therapeutic Patents","issn_l":"1354-3776","issn":["1354-3776","1744-7674"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Therapeutic Patents","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5031152143","display_name":"Llu\u00eds Pag\u00e8s","orcid":"https://orcid.org/0000-0002-3367-9529","observed_orcids":["https://orcid.org/0000-0002-3367-9529"]},"institutions":[{"id":"https://openalex.org/I4210122008","display_name":"Almirall (Spain)","ror":"https://ror.org/03qsven24","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210122008"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Llu\u00eds Pag\u00e8s","raw_affiliation_strings":["Almirall R&D Centre, Department of Medicinal Chemistry, Laure\u00e0 Mir\u00f3 408-410, 08980 Sant Feliu de Llobregat, Barcelona, Spain. Lluis.pages@almirall.com","+34 93 2913420","Almirall R&D Centre, Department of Medicinal Chemistry, Laure\u00e0 Mir\u00f3 408-410, 08980 Sant Feliu de Llobregat, Barcelona, Spain +34 93 2913587"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Almirall R&D Centre, Department of Medicinal Chemistry, Laure\u00e0 Mir\u00f3 408-410, 08980 Sant Feliu de Llobregat, Barcelona, Spain. Lluis.pages@almirall.com","institution_ids":["https://openalex.org/I4210122008"]},{"raw_affiliation_string":"+34 93 2913420","institution_ids":[]},{"raw_affiliation_string":"Almirall R&D Centre, Department of Medicinal Chemistry, Laure\u00e0 Mir\u00f3 408-410, 08980 Sant Feliu de Llobregat, Barcelona, Spain +34 93 2913587","institution_ids":["https://openalex.org/I4210122008"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011422133","display_name":"Amadeu Gavald\u00e0","orcid":"https://orcid.org/0000-0001-7042-0041","observed_orcids":["https://orcid.org/0000-0001-7042-0041"]},"institutions":[{"id":"https://openalex.org/I4210122008","display_name":"Almirall (Spain)","ror":"https://ror.org/03qsven24","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210122008"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Amadeu Gavald\u00e0","raw_affiliation_strings":["Almirall R&D Centre, Department of Pharmacology, Laure\u00e0 Mir\u00f3 408-410, 08980 Sant Feliu de Llobregat, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Almirall R&D Centre, Department of Pharmacology, Laure\u00e0 Mir\u00f3 408-410, 08980 Sant Feliu de Llobregat, Barcelona, Spain","institution_ids":["https://openalex.org/I4210122008"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5103479765","display_name":"Martin D. Lehner","orcid":"https://orcid.org/0009-0001-3279-1092","observed_orcids":["https://orcid.org/0009-0001-3279-1092"]},"institutions":[{"id":"https://openalex.org/I4210122008","display_name":"Almirall (Spain)","ror":"https://ror.org/03qsven24","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210122008"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Martin D Lehner","raw_affiliation_strings":["Almirall R&D Centre, Respiratory Therapeutic Area - Discovery, Laure\u00e0 Mir\u00f3 408-410, 08980 Sant Feliu de Llobregat, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Almirall R&D Centre, Respiratory Therapeutic Area - Discovery, Laure\u00e0 Mir\u00f3 408-410, 08980 Sant Feliu de Llobregat, Barcelona, Spain","institution_ids":["https://openalex.org/I4210122008"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210122008"],"apc_list":null,"apc_paid":null,"fwci":0.9519,"has_fulltext":false,"cited_by_count":103,"citation_normalized_percentile":{"value":0.6904059,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"19","issue":"11","first_page":"1501","last_page":"1519"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12434","display_name":"Phosphodiesterase function and regulation","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12434","display_name":"Phosphodiesterase function and regulation","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11193","display_name":"Adenosine and Purinergic Signaling","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1314","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/phosphodiesterase-4-inhibitors","display_name":"phosphodiesterase-4 inhibitors","score":0.9860000014305115},{"id":"https://openalex.org/keywords/phosphodiesterase-4","display_name":"phosphodiesterase 4","score":0.8299999833106995},{"id":"https://openalex.org/keywords/roflumilast","display_name":"roflumilast","score":0.9110000133514404},{"id":"https://openalex.org/keywords/topical-drug-delivery","display_name":"topical drug delivery","score":0.7099999785423279},{"id":"https://openalex.org/keywords/systemic-side-effects","display_name":"systemic side effects","score":0.6990000009536743},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.7850000262260437},{"id":"https://openalex.org/keywords/clinical-drug-development","display_name":"clinical development","score":0.5389999747276306},{"id":"https://openalex.org/keywords/patent-literature","display_name":"patent literature","score":0.906000018119812},{"id":"https://openalex.org/keywords/inflammatory-diseases","display_name":"inflammatory diseases","score":0.7070000171661377},{"id":"https://openalex.org/keywords/neurological-disorders","display_name":"neurological disorders","score":0.8569999933242798},{"id":"https://openalex.org/keywords/isoform-selective-inhibitors","display_name":"isoform-selective inhibitors","score":0.6690000295639038}],"concepts":[{"id":"https://openalex.org/C148043351","wikidata":"https://www.wikidata.org/wiki/Q4456944","display_name":"Current (fluid)","level":2,"score":0.5465256571769714},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.375004380941391},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.33845606446266174},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.33652204275131226},{"id":"https://openalex.org/C127413603","wikidata":"https://www.wikidata.org/wiki/Q11023","display_name":"Engineering","level":0,"score":0.14005964994430542},{"id":"https://openalex.org/C119599485","wikidata":"https://www.wikidata.org/wiki/Q43035","display_name":"Electrical engineering","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000631","descriptor_name":"Aminopyridines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000631","descriptor_name":"Aminopyridines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003521","descriptor_name":"Cyclopropanes","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003521","descriptor_name":"Cyclopropanes","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007249","descriptor_name":"Inflammation","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D007249","descriptor_name":"Inflammation","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D009422","descriptor_name":"Nervous System Diseases","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009422","descriptor_name":"Nervous System Diseases","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D010330","descriptor_name":"Patents as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010726","descriptor_name":"Phosphodiesterase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D010726","descriptor_name":"Phosphodiesterase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058988","descriptor_name":"Phosphodiesterase 4 Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1517/13543770903313753","doi":"https://doi.org/10.1517/13543770903313753","is_oa":false,"landing_page_url":"https://doi.org/10.1517/13543770903313753","pdf_url":null,"source":{"id":"https://openalex.org/S3784663","display_name":"Expert Opinion on Therapeutic Patents","issn_l":"1354-3776","issn":["1354-3776","1744-7674"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Therapeutic Patents","raw_type":"journal-article"},{"id":"pmid:19832118","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19832118","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on therapeutic patents","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320324177","display_name":"Otsuka Pharmaceutical","ror":"https://ror.org/013k5y296"},{"id":"https://openalex.org/F4320331744","display_name":"Almirall","ror":"https://ror.org/03qsven24"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":26,"referenced_works":["https://openalex.org/W139570440","https://openalex.org/W1964343782","https://openalex.org/W1967221897","https://openalex.org/W1980481083","https://openalex.org/W1983563799","https://openalex.org/W1988901842","https://openalex.org/W2001965102","https://openalex.org/W2026527102","https://openalex.org/W2029299795","https://openalex.org/W2052400036","https://openalex.org/W2053116295","https://openalex.org/W2059714502","https://openalex.org/W2061338042","https://openalex.org/W2076204287","https://openalex.org/W2090662888","https://openalex.org/W2101175089","https://openalex.org/W2121686900","https://openalex.org/W2134278083","https://openalex.org/W2141323574","https://openalex.org/W2148003974","https://openalex.org/W2151950207","https://openalex.org/W2170451911","https://openalex.org/W2172258989","https://openalex.org/W2332486188","https://openalex.org/W2335515876","https://openalex.org/W4256102116"],"related_works":["https://openalex.org/W1964343782","https://openalex.org/W2131136400","https://openalex.org/W4289939887","https://openalex.org/W2018104937","https://openalex.org/W172480577","https://openalex.org/W2916202431","https://openalex.org/W4205200081","https://openalex.org/W2272532961","https://openalex.org/W2329467142","https://openalex.org/W3147458129"],"abstract_inverted_index":{"BACKGROUND:":[0],"Despite":[1],"the":[2,18,35,45,58,71,81,95,104,150],"sound":[3],"preclinical":[4],"database":[5],"and":[6,75,103,142],"some":[7],"promising":[8],"data":[9],"from":[10],"clinical":[11,96,133],"trials,":[12,134],"development":[13,97],"of":[14,20,48,54,60,73,84,98,125,138],"PDE4":[15,55,89,99,154],"inhibitors":[16,56,100],"for":[17,40,129],"treatment":[19],"inflammatory":[21],"or":[22],"neurological":[23],"diseases":[24],"has":[25,145],"been":[26,146],"hampered":[27],"by":[28,70],"dose-limiting":[29],"class-related":[30],"side":[31],"effects.":[32,118],"OBJECTIVE:":[33],"In":[34,119],"past":[36],"years,":[37],"companies":[38],"opted":[39],"different":[41],"approaches":[42],"to":[43,114],"improve":[44],"therapeutic":[46],"window":[47],"their":[49],"compounds":[50],"including":[51],"topical":[52],"administration":[53],"with":[57,108,149],"goal":[59],"minimizing":[61],"systemic":[62,116],"exposure.":[63],"This":[64,92],"change":[65],"in":[66,87],"strategy":[67],"is":[68],"reflected":[69],"disclosure":[72],"novel":[74],"chemically":[76],"diverse":[77],"molecules":[78],"that":[79],"demonstrate":[80],"continued":[82],"interest":[83],"pharmaceutical":[85],"industry":[86],"developing":[88],"inhibitors.":[90],"CONCLUSION:":[91],"review":[93],"summarizes":[94],"since":[101],"2005":[102],"associated":[105],"patent":[106],"literature":[107],"a":[109,122],"focus":[110],"on":[111],"strategies":[112],"applied":[113],"minimize":[115],"adverse":[117],"sum,":[120],"although":[121],"significant":[123],"number":[124],"new":[126],"drugs":[127],"designed":[128],"improved":[130],"tolerability":[131],"entered":[132],"so":[135],"far":[136],"none":[137],"them":[139],"fulfilled":[140],"expectations":[141],"best":[143],"progress":[144],"achieved":[147],"recently":[148],"oral,":[151],"non-isoform":[152],"selective":[153],"inhibitor":[155],"roflumilast.":[156]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":9},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":10},{"year":2013,"cited_by_count":12},{"year":2012,"cited_by_count":11}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-06-24T00:00:00"}